Please complete all required questions before submission.
Ketamine is a medication that has been used safely in medicine, primarily in anesthesia and pain management. Ketamine is made up of two forms of the same molecule, known as enantiomers: S-ketamine (esketamine) and R-ketamine (arketamine). Research shows that ketamine, at lower doses than those used for anesthesia, may help relieve symptoms of depression in some individuals who have not responded well to traditional treatments.
Esketamine is the S-enantiomer of ketamine and is the active ingredient in Spravato. Studies suggest that esketamine is more potent than racemic ketamine, meaning it can be used at lower doses and may result in fewer side effects. Unlike many traditional antidepressants that work on serotonin and related brain chemicals, esketamine acts primarily on the glutamate system, which plays an important role in brain connectivity and mood regulation.
Esketamine works on the glutamatergic system in the brain and is thought to help create new connections, called synapses, between brain cells. In depression, these connections may become reduced or weakened. Esketamine may help restore these connections, which can lead to improvement in mood, thinking, and emotional regulation.
Spravato is used, along with appropriate medical supervision, for the treatment of:
Spravato is approved by the FDA and must be given in a certified healthcare setting.
Spravato is considered a safe and effective depression treatment when administered by properly trained healthcare professionals in a certified healthcare setting. Every patient is evaluated and monitored to ensure that treatment is appropriate and safe.
Spravato is esketamine, which is related to ketamine. Ketamine has been misused as a recreational drug at very high doses outside of medical settings. These doses are far higher than what is used for depression treatment. Spravato is prescribed legally, administered in a medical setting, and carefully monitored. It is not provided for home use. Like many medications used in medicine, there is potential for misuse. For this reason, all patients are monitored for signs of abuse or misuse.
Spravato is administered only as an intranasal nasal spray. Most research studies on esketamine for depression have been conducted using intranasal Spravato. This method has been shown to be the most effective and predictable way to deliver the medication for this condition. For this reason, intranasal administration is considered the standard method for Spravato treatment.
Research over the past several years has shown that many people with severe or treatment-resistant depression experience significant improvement with Spravato treatment. While many patients benefit, results vary. Some patients notice improvement quickly, while others experience more gradual changes. In some cases, improvement may be subtle at first. Spravato does not always produce an immediate dramatic effect. We will work closely with you to evaluate your response and adjust treatment as needed.
The standard treatment protocol usually involves treatments twice per week for the first four weeks. This is followed by weekly treatments for several weeks and then maintenance treatments, often every one to two weeks. Many patients who respond to Spravato require ongoing maintenance treatments. The frequency of these treatments varies from person to person. Spravato should be viewed as part of a long-term treatment plan rather than a one-time cure.
Yes. You should continue taking your prescribed antidepressant medications unless your provider instructs you otherwise. It is very important that we review your complete medication list before starting treatment and at each visit. This includes prescriptions, over-the-counter medications, supplements, and herbal products.
Spravato is not considered physically addictive when used as prescribed in a medical setting. However, there is potential for misuse when Spravato is used recreationally or outside of medical supervision. Because of this, all patients are monitored for signs of abuse or misuse throughout treatment. If concerns arise, treatment may be adjusted or discontinued.
Spravato contains esketamine and is delivered through a nasal spray. Ketamine infusions use racemic ketamine and are administered intravenously. There are currently no large head-to-head studies comparing Spravato nasal spray with ketamine infusions. Both are used in clinical practice, but Spravato is FDA-approved for depression and is regulated through a REMS program.
The cost of Spravato depends on your insurance plan and coverage. Assistance programs may be available through the manufacturer or other programs. Our staff will work with you and your insurance company to help determine coverage and out-of-pocket costs.
If you miss a scheduled treatment and your depression symptoms worsen, your provider may recommend returning to your previous dosing schedule. Treatment plans are individualized and may be adjusted based on your response and clinical needs.
No. Under the REMS program, Spravato must be administered in a certified healthcare setting. Patients are required to remain under medical observation for at least two hours after each treatment to ensure safety. Spravato is not prescribed for home use.
Spravato may impair your ability to drive or operate machinery. You must not drive or engage in hazardous activities until the next day after a full night of restful sleep. This restriction is required for your safety and the safety of others.
Your first visit will include a comprehensive evaluation of your physical and mental health. Your provider will review current medications, and engagement in psychiatric treatment. You will also be asked to complete questionnaires and sign consent forms. Your blood pressure will be checked before treatment. If it is too high, treatment may be postponed. During treatment, you will be seated comfortably and monitored. You may experience mild dizziness, dissociation, or nausea. You will remain awake and able to communicate. After treatment, you will remain under observation for a total of two hours before being discharged with a responsible adult.
To support your safety and the effectiveness of treatment, please follow these instructions before each Spravato session.
Spravato works best as part of a comprehensive treatment plan that may include therapy, medication management, lifestyle support, and recovery-oriented services. Attend scheduled appointments with your care team.
After receiving Spravato, you may experience temporary physical, emotional, or cognitive effects. These instructions are designed to help you recover safely.